Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Docetaxel (Taxotere), Carboplatin, and Gemcitabine (DoCaGem) as First-Line Therapy for Patients With High-Risk Epithelial Tumors of Mullerian Origin

NCT00004082 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

NCT NCT00004082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Docetaxel (Taxotere), Carboplatin, and Gemcitabine (DoCaGem) as First-Line Therapy for Patients With High-Risk Epithelial Tumors of Mullerian Origin
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Phase 1
Overall status
Completed
Start date
July 31, 1999
Completion date
December 31, 2010
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer